Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| Weiss Ratings | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.04 | |||
| Price History | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.25% | |||
| 30-Day Total Return | -7.58% | |||
| 60-Day Total Return | -14.15% | |||
| 90-Day Total Return | -18.42% | |||
| Year to Date Total Return | -11.57% | |||
| 1-Year Total Return | -35.30% | |||
| 2-Year Total Return | 10.58% | |||
| 3-Year Total Return | 17.49% | |||
| 5-Year Total Return | 200.49% | |||
| 52-Week High % Change | -42.04% | |||
| 52-Week Low % Change | 8.27% | |||
| Price | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $75.71 | |||
| 52-Week Low Price | $40.53 | |||
| 52-Week Low Price (Date) | Feb 12, 2025 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.20B | |||
| Enterprise Value | 5.04B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.28 | |||
| Earnings Per Share Growth | -3.20% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 280.56 | |||
| Price/Book (Q) | -38.32 | |||
| Enterprise Value/Revenue (TTM) | 272.98 | |||
| Price | $43.27 | |||
| Enterprise Value/EBITDA (TTM) | -9.57 | |||
| Enterprise Value/EBIT | -9.40 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 118.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 624 3000 | |||
| Address | 350 Oyster Point Boulevard South San Francisco, CA 94080 | |||
| Website | www.cytokinetics.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,902.71% | |||
| Profit Margin | -3,191.11% | |||
| Management Effectiveness | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -30.11% | |||
| Return on Equity | -- | |||
| Income Statement | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 18.47M | |||
| Total Revenue (TTM) | 18.47M | |||
| Revenue Per Share | $0.16 | |||
| Gross Profit (TTM) | -320.93M | |||
| EBITDA (TTM) | -526.72M | |||
| EBIT (TTM) | -536.25M | |||
| Net Income (TTM) | -589.53M | |||
| Net Income Avl. to Common (TTM) | -589.53M | |||
| Total Revenue Growth (Q YOY) | 912.38% | |||
| Earnings Growth (Q YOY) | -9.59% | |||
| EPS Diluted (TTM) | -5.28 | |||
| EPS Diluted Growth (Q YOY) | 8.06% | |||
| Balance Sheet | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.08B | |||
| Cash Per Share (Q) | $9.11 | |||
| Total Current Assets (Q) | 1.11B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -135.37M | |||
| Current Ratio (Q) | 6.166 | |||
| Book Value Per Share (Q) | -$1.15 | |||
| Total Assets (Q) | 1.40B | |||
| Total Current Liabilities (Q) | 179.67M | |||
| Total Debt (Q) | 923.18M | |||
| Total Liabilities (Q) | 1.54B | |||
| Total Common Equity (Q) | -135.37M | |||
| Cash Flow | CYTK - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -553.10M | |||
| Cash from Financing (TTM) | 930.61M | |||
| Net Change in Cash (TTM) | -18.17M | |||
| Levered Free Cash Flow (TTM) | -240.50M | |||
| Cash from Operations (TTM) | -395.89M | |||
